



Final Appraisal Recommendation

Advice No: 3415 – November 2015

Tedizolid phosphate (Sivextro[®]▼) 200 mg film-coated tablets/200 mg powder for concentrate for solution for infusion

Submission by Merck Sharp & Dohme Ltd

Recommendation of AWMSG

Tedizolid phosphate (Sivextro[®]▼) is recommended as an option for restricted use within NHS Wales for the treatment of adult patients with acute bacterial and skin structure infections (ABSSSI) caused by Gram-positive *Staphylococcus aureus* (specifically methicillin-resistant [MRSA] isolates) as an alternative oxazolidinone antibacterial. Treatment should only be initiated on advice from local microbiologists or specialists in infectious diseases.

Tedizolid phosphate (Sivextro[®]▼) is not recommended for use within NHS Wales outside of this subpopulation/circumstance.

Additional note(s):

- The company did not submit evidence for AWMSG to consider on the use of tedizolid phosphate in 'mixed infections'; that is, where the infection involves both Gram-positive and Gram-negative organisms.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1607), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.



Marketing authorisation holder on first issue	Merck Sharp & Dohme Ltd
Date of first issue	November 2015
Last reviewed	April 2019

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 3415:
tedizolid phosphate (Sivextro[®]) 200 mg film-coated tablets/200 mg powder for concentrate for
solution for infusion. November 2015.